ChinaDrugStatus

Insulin icodec / Semaglutide

依柯胰岛素司美格鲁肽
Brand: Kyinsu / 诺和杰·Endocrinology / Metabolic·Last verified 2026-11-20

Fixed-ratio once-weekly basal insulin and GLP-1 agonist combination (IcoSema) newly added to the 2026 NRDL Negotiated List (#18) for adult T2D.

China Approval (NMPA)

Approved
Approval Number(s)
国药准字SJ20260018
Initial Approval Date
Oct 15, 2026
Notice Published
Oct 15, 2026
MAH
Novo Nordisk A/S (诺和诺德)
Approved Scope
Expanded to adults with Type 2 Diabetes inadequately controlled on oral antidiabetic drugs (OADs); initial March 2026 approval covered patients uncontrolled on basal insulin or GLP-1 RAs.

National Reimbursement

Announced · Effective Jan 1, 2027
2026 Edition Entry
Negotiated #18 · Class B
Agreement Period
2027-01-01 to 2028-12-31
Payment Standard
* Confidential (marked with asterisk in NHSA PDF)
2026 Payment Scope
Restricted to adults with Type 2 Diabetes mellitus inadequately controlled on basal insulin or a GLP-1 receptor agonist.
限接受基础胰岛素或胰高糖素样肽1(GLP-1)受体激动剂治疗后血糖控制不佳的成人2型糖尿病患者。

Commercial Insurance List

Not Listed

Not listed in the 2025 or 2026 NHSA Commercial Health Insurance Innovative Drug List.

Approved Products, Dosage Forms & Approval Numbers

1 verified NMPA record
Approval No.Dosage Form & StrengthEvent & ScopeApproval / Notice DateMAH & Source
国药准字SJ20260018
Injection (注射液)
Pre-filled pen (SJ20260018 / SJ20260019 / SJ20260020)
Supplemental Indication

Expanded to adults with Type 2 Diabetes inadequately controlled on oral antidiabetic drugs (OADs); initial March 2026 approval covered patients uncontrolled on basal insulin or GLP-1 RAs.

新增适用于接受口服降糖药(OADs)治疗血糖控制不佳的成人2型糖尿病患者(首发适应症于2026年3月获批用于基础胰岛素或GLP-1RA控制不佳患者)。

Approved: 2026-10-15
Published: 2026-10-15
Novo Nordisk A/S

Change Timeline

  1. (2027-01-01)Basic NRDL· Catalog published: Nov 14, 2026

    2026 NRDL · Added to Negotiated List

    Newly added to 2026 NRDL Negotiated List (#18, Class B, *) for adult T2D inadequately controlled on basal insulin or GLP-1 receptor agonist.

    Chinese original: 新增纳入2026版谈判药品第18项(乙类,支付标准*),限基础胰岛素或GLP-1受体激动剂控制不佳的成人2型糖尿病患者。

    NHSA · PDF p.118Verified 2026-11-20
  2. (2026-10-15)NMPA Approval

    NMPA Supplemental Indication Approval (国药准字SJ20260018 · Pre-filled pen (SJ20260018 / SJ20260019 / SJ20260020))

    Expanded to adults with Type 2 Diabetes inadequately controlled on oral antidiabetic drugs (OADs); initial March 2026 approval covered patients uncontrolled on basal insulin or GLP-1 RAs.

    Chinese original: 新增适用于接受口服降糖药(OADs)治疗血糖控制不佳的成人2型糖尿病患者(首发适应症于2026年3月获批用于基础胰岛素或GLP-1RA控制不佳患者)。

Verified Names & Aliases

Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.

依柯胰岛素司美格鲁肽注射液dosage name(NHSA)
IcoSemacode(WHO)
Kyinsubrand en(NMPA)
诺和杰brand zh(NMPA)

Primary Sources for This Record